Immunotherapy is a type of biological therapy that uses the immune system to help destroy cancer cells.[1]
Bacillus Calmette–Guérin (BCG)
Immunotherapy by intravesicular delivery of Bacillus Calmette–Guérin (BCG) is often used to treat and prevent the recurrence of superficial tumors.[2]
BCG is a vaccine against tuberculosis that is prepared from attenuated live Mycobacterium bovis, that has lost its virulence in humans. BCG immunotherapy is effective in up to 2/3 of the cases at this stage, and in randomized trials has been shown to be superior to standard chemotherapy.[3]
The mechanism by which BCG prevents recurrence is unknown, but the presence of bacteria in the bladder may trigger a localized immune reaction which clears residual cancer cells.
During intravesical chemotherapy, the drugs are placed into the bladder through a urinary catheter.[4][5]
Intravesical chemotherapy may be given instead of BCG or if the bladder cancer doesn’t respond to BCG.[6]
Mitomycin is the drug most often used in intravesical chemotherapy.[7][8]
Systemic chemotherapy
During systemic chemotherapy, the drugs are given intravenously.
Systemic chemotherapy may be a treatment option for bladder cancer that has spread to other tissues near the bladder and bladder cancer that has spread to other parts of the body.[9]
Chemotherapy is recommended before a radical cystectomy (called neoadjuvant chemotherapy) for many people with bladder cancer that has grown into the muscle layer of the bladder wall. It is also often given after a radical cystectomy (called adjuvant chemotherapy) to people with high-risk features such as cancer that has spread to lymph nodes.[10]
↑Ghahestani SM, Shakhssalim N (2009). "Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review". Urol J. 6 (3): 149–56. PMID19711266.
↑Alexandroff AB, Jackson AM, O'Donnell MA, James K (May 1999). "BCG immunotherapy of bladder cancer: 20 years on". Lancet. 353 (9165): 1689–94. doi:10.1016/S0140-6736(98)07422-4. PMID10335805.CS1 maint: Multiple names: authors list (link)
↑Volpe A, Racioppi M, D'Agostino D, Cappa E, Filianoti A, Bassi PF (June 2010). "Mitomycin C for the treatment of bladder cancer". Minerva Urol Nefrol. 62 (2): 133–44. PMID20562793.
↑Konski A, Feigenberg S, Chow E (April 2005). "Palliative radiation therapy". Semin. Oncol. 32 (2): 156–64. PMID15815960.
↑Kaufman DS, Shipley WU, Althausen AF (February 1992). "Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing". Hematol. Oncol. Clin. North Am. 6 (1): 179–94. PMID1556049.